Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Deferred Tax (2020 - 2023)

InMed Pharmaceuticals has reported Long-Term Deferred Tax over the past 3 years, most recently at $21.0 million for Q2 2023.

  • For Q2 2023, Long-Term Deferred Tax rose 12.56% year-over-year to $21.0 million; the TTM value through Jun 2023 reached $21.0 million, up 12.56%, while the annual FY2023 figure was $21.0 million, 12.56% up from the prior year.
  • Long-Term Deferred Tax for Q2 2023 was $21.0 million at InMed Pharmaceuticals, up from $18.7 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $21.0 million in Q2 2023 and troughed at $259457.0 in Q2 2021.
  • A 3-year average of $13.3 million and a median of $18.7 million in 2022 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 7100.28% in 2022 and later increased 12.56% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $259457.0 in 2021, then soared by 7100.28% to $18.7 million in 2022, then grew by 12.56% to $21.0 million in 2023.
  • Business Quant data shows Long-Term Deferred Tax for INM at $21.0 million in Q2 2023, $18.7 million in Q2 2022, and $259457.0 in Q2 2021.